Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 2 sources · 19 days · First seen · Last updated
Acacia Research earnings and stock performance
Overview
In mid‑July, Acacia Research Corp. saw its shares climb above the 200‑day moving average after reporting a quarterly loss of $0.07 per share that beat expectations. Revenue of $54.24 million and modest new institutional positions were noted, while analysts offered mixed opinions, including a downgrade to sell.
By early August, Acacia posted a markedly stronger quarter, delivering earnings of $0.13 per share and revenue of $114.56 million—far surpassing forecasts. The company highlighted a robust cash balance of $334.6 million and an active acquisition pipeline, which helped sustain the stock around $4.54. Analyst coverage remained varied, but the earnings beat signaled a shift from the previous loss‑beat narrative.
Overall, the two updates trace Acacia Research’s rapid transition from narrowly beating loss expectations with modest revenue to achieving a profitable quarter with significantly higher sales and cash reserves, while analyst sentiment continued to fluctuate.
Entities
Nasdaq · Acacia Research Inc. · Benchmark · IDEAYA Biosciences Inc. · Truist Financial
Timeline
-
24 days ago
[BUSINESS] 2 sourcesAcacia Research Beats Estimates as IDEAYA Biosciences Receives Lower Price TargetAcacia Research posted a $0.13 EPS beat with $114.6M revenue; IDEAYA Biosciences got a reduced $59 price target, stock at $36.34.
-
about 1 month ago
[BUSINESS] 2 sourcesAcacia Research and Tectonic Therapeutic shares rise as analysts adjust ratingsAcacia Research stock climbed above its 200‑day average to $4.55, beating earnings estimates, while Tectonic Therapeutic rose 6% to $32.58 amid mixed analyst ratings and a quarterly loss.
Sources
mommygearest.com · stocknews.com